Paroxysmal Nocturnal Hemoglobinuria
A rare acquired disorder of the blood-forming cells that leads to destruction of red blood cells and an increased risk of dangerous blood clots, requiring specialist hematology management.
- Complement inhibitor therapy
- Specialist hematology review
- Long-term monitoring support
- Disease Type
- Rare Acquired Disorder
- Underlying Cause
- GPI-Anchor Deficiency
- Key Risks
- Hemolysis, Thrombosis
- Advanced Therapies
- Complement Inhibitors
Condition Overview
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of blood-forming stem cells. It results from a somatic mutation in the PIGA gene, which leads to a deficiency of GPI-anchored proteins that normally protect red blood cells from the body's own complement system.
Without this protection, red blood cells are destroyed prematurely, a process called hemolysis. This can cause dark urine (classically darker in the morning, which gave the condition its name), fatigue, and a significantly increased risk of blood clots, which is one of the most serious complications of PNH.
PNH can occur on its own or alongside other bone marrow disorders, particularly aplastic anemia. Because it is rare and its symptoms overlap with other conditions, diagnosis is sometimes delayed, making evaluation by a hematologist experienced with PNH important.
Types and Subtypes
PNH is generally described by its clinical presentation and whether it occurs alongside other bone marrow disorders.
Symptoms and Signs
Symptoms of PNH relate primarily to hemolysis (red blood cell destruction) and the increased tendency to form blood clots.
Causes and Risk Factors
PNH is caused by an acquired genetic change rather than something inherited from a parent, and its risk factors differ from most other blood disorders.
Diagnosis and Investigations
Diagnosis of PNH relies on specialized blood tests that detect the absence of GPI-anchored proteins on blood cells.
Disease Risk Stratification
PNH does not use a traditional cancer staging system. Instead, management is guided by disease severity, based on the extent of hemolysis, clone size, and prior thrombotic events.
Standard Treatment
Treatment of PNH is individualized based on symptom severity, hemolysis, and clotting risk.
Advanced & Emerging Therapies
Treatment of PNH has been transformed by complement-targeted therapies, and newer agents continue to expand options.
Complement Inhibitor
C5 Inhibitors (Eculizumab, Ravulizumab)
Block a key step in the complement cascade, substantially reducing hemolysis and clot risk; the current standard for significant PNH.
Complement Inhibitor
Proximal (C3) Complement Inhibitors
Newer oral or injectable agents that act earlier in the complement pathway and may help patients with residual hemolysis on C5 inhibitors.
Cellular Therapy
Allogeneic Stem Cell Transplant
Considered for patients with concurrent severe bone marrow failure, offering a potentially curative option.
Precision Medicine
Investigational Complement-Targeted Agents
Several next-generation complement inhibitors are being studied to further reduce breakthrough hemolysis and improve dosing convenience.
Biomarkers & Precision Medicine
Laboratory markers help characterize disease activity and guide treatment decisions in PNH.
When to Seek a Second Opinion
Because PNH is rare, specialist input from a hematologist experienced in complement-mediated disorders can be particularly valuable.
Clinical Trials & Research
Prognosis & Outcomes
The outlook for PNH has changed substantially with the introduction of complement inhibitor therapy, which has reduced the impact of thrombosis as a cause of serious illness. Outcomes vary depending on clone size, presence of bone marrow failure, and response to treatment.
Supportive Care
Supportive care addresses the effects of chronic hemolysis and helps reduce complication risk in PNH.
How CancerFax Helps You Explore Treatment Options
CancerFax can help coordinate medical report review, second opinions, and access to specialists experienced in PNH and complement inhibitor therapy.
Get a free case reviewFrequently Asked Questions
Paroxysmal nocturnal hemoglobinuria is a rare, acquired blood disorder in which red blood cells lack protective proteins, making them vulnerable to destruction by the body's own complement system. This leads to hemolysis and an increased risk of blood clots.
No. PNH is a non-malignant disorder of blood-forming stem cells, though it can occur alongside other bone marrow conditions such as aplastic anemia.
The name reflects the classic, though not universal, finding of darker urine in the morning due to hemolysis occurring overnight, although urine color changes can occur at any time of day.
No. PNH results from an acquired mutation in a blood stem cell during a person's lifetime, not from a mutation inherited from a parent, and it is not passed on to children.
Complement inhibitor medications, such as eculizumab and ravulizumab, are the main treatment for significant PNH, reducing hemolysis and lowering the risk of blood clots.
Allogeneic stem cell transplant can be curative but is generally reserved for patients with PNH alongside severe bone marrow failure, given the risks involved. For most patients, complement inhibitor therapy provides long-term disease control.
PNH increases the risk of blood clots, sometimes in unusual locations such as abdominal or brain veins, and thrombosis has historically been a leading cause of serious complications in this condition.
Yes, meningococcal vaccination is generally recommended before starting complement inhibitor therapy, since these medications increase susceptibility to certain infections.
Monitoring frequency depends on disease severity and treatment, but generally includes regular blood counts and hemolysis markers to track response and detect breakthrough disease.
Yes. CancerFax can help you organize and share your medical reports for specialist hematology review, coordinate a second opinion, explore access to complement inhibitor therapies and clinical trials, and support cross-border coordination with international treatment centers if that is part of your care plan.
Get Expert Guidance on Your PNH Diagnosis
Share your medical reports with our team to explore treatment options, second opinions, and access to complement inhibitor therapies.